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A B S T R A C T
Objectives: People who inject drugs are at high risk of HIV infection but often face barriers in accessing
medical care including access to antiretroviral therapy (ART). Evidence is available about the
effectiveness of opioid agonist therapy on drug dependency and risk behaviors. However, it remains
scattered regarding access to ART among HIV-positive people who inject drugs. We conducted a
systematic review to examine the association of opioid agonist therapy with ART initiation among HIV-
positive people who inject drugs.
Methods: We searched the literature for evidence from seven databases. We conducted a narrative
synthesis and meta-analysis to examine the association of opioid agonist therapy with ART initiation.
Results: Five out of 2,901 identiﬁed studies met the inclusion criteria. Three out of ﬁve studies reported
that, HIV-positive people receiving opioid agonist therapy initiated ART more than those not receiving
opioid agonist therapy. In meta-analysis, opioid agonist therapy was associated with ART initiation
among HIV positive people who inject drugs (pooled odds ratio: 1.68; 95% conﬁdence interval: 1.03–
2.73).
Conclusions: Opioid agonist therapy is positively associated with ART initiation among HIV-positive
people who inject drugs. It is important to scale up opioid agonist therapy among people who inject
drugs to improve their ART initiation.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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People who inject drugs are at high risk of contracting human
immunodeﬁciency virus (HIV) infection, owing to their high-risk
injecting,1 and sexual behaviors.2 About 1.7 out of 12.2 million
people who injected drugs were infected with HIV in 2013.3 This
population is recognized as a point source of HIV infection for the
general populations, both in concentrated and generalized
epidemics. They may engage in high-risk sexual behaviors with
their injecting or non-injecting drug use partners. Unrestricted* Corresponding author.
E-mail addresses: lindasozy@gmail.com (L.B. Mlunde), sunguya@gmail.com
(B.F. Sunguya), jmbwambo@gmail.com (J.K.K. Mbwambo), oubuguyu@yahoo.com
(O.S. Ubuguyu), jyasuoka@post.harvard.edu (J. Yasuoka), mjimba@m.u-tokyo.ac.jp
(M. Jimba).
http://dx.doi.org/10.1016/j.ijid.2016.03.022
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).access of HIV care by people who inject drugs is necessary to
control the HIV epidemic.
Many people who inject drugs do not have access to
antiretroviral therapy (ART) despite their need. ART improves
morbidity and mortality4,5 and prolongs lives of HIV-positive
individuals. ART may also decrease the transmission of HIV
infection.6–8 Only four out of 100 HIV-positive people who inject
drugs receive ART in 47 countries where reports of ART use were
available among people who inject drugs.9 People who inject drugs
face various barriers to access ART and other health care services.
People who use drugs do not often trust the health care system and
expect that they will be treated punitively.10 They sometimes
perceive discrimination and fear of negative reactions from health
workers.11 In addition, people who use drugs may be denied
treatment due to co-morbidity of medical conditions12,13 and
medical practitioners’ fear of inadequate compliance to treatment,
once initiated.12,14ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
L.B. Mlunde et al. / International Journal of Infectious Diseases 46 (2016) 27–3328Treatment of opioid dependence may improve access to ART
among people who inject drugs.15,16 Medications for opioid
dependence can either be agonists such as methadone or partial
agonists such as buprenorphine or antagonists such as naloxone.17
However, provision of opioid agonist therapy to people who inject
drugs is still low. For instance, less than 2% of people who inject
drugs are provided with opioid agonist therapy in each of the
following ﬁve countries: China, Malaysia, Russia, Ukraine and
Vietnam. Almost half of all HIV-positive people who inject drugs
live in these ﬁve countries.18 In an opioid agonist therapy program,
people who inject drugs receive medications to treat opioid
dependence.19
Opioid agonist therapy programs may be linked to medical
services. This allows provision of medical care at the harm
reduction sites20,21 Additionally, people who inject drugs may be
referred to nearby medical clinics or specialized care facilities
when in need.22 Such medical care may include primary medical
care, ART, and hepatitis treatment services. In addition, opioid
agonist therapy improves physical and social functioning of
clients.23,24 These provisions are more likely to help people who
inject drugs achieve physical and social stabilization and overcome
barriers of access to ART. Although such evidence is available, no
systematic review has been conducted to examine the association
of opioid agonist therapy with ART initiation among HIV-positive
people who inject drugs. Therefore, we conducted this systematic
review to examine the association of opioid agonist therapy with
ART initiation among HIV-positive people who inject drugs. The
results of this review will assist policy makers in making decisions
about the problem of low ART coverage among people who inject
drugs.
2. Methods
This systematic review aimed to answer the following
population, intervention, comparator, and outcome (PICO) ques-
tion: ‘‘What is the association of opioid agonist therapy with ART
initiation among people who inject drugs who are on opioid
agonist therapy compared to those who are not on such therapy?’’
In this review, we deﬁned the population as people who use illicit
drugs by means of injection and are living with HIV regardless of
their age. The intervention was being on opioid agonist therapy. In
such interventions, clients receive medications such as buprenor-
phine and methadone for treating opioid dependence.19,25 The
comparison group consisted of people who use illicit drugs by
means of injection and are living with HIV but are not on opioid
agonist therapy. The outcome of interest was ART initiation.
We excluded studies which included people who inject drugs
enrolled in detoxiﬁcation centers from our review. These centers
are used to minimize withdrawal symptoms of addicted clients in a
safe and effective manner. We excluded these studies because,
detoxiﬁcation processes in such centers may or may not involve
the use of medications such as methadone and buprenorphine.26
We ﬁrst developed a protocol and registered it at the PROSPERO
database for systematic reviews (Supplementary ﬁle 1). The
registration number of the protocol is CRD42014009118.27 In this
registered protocol, the primary outcome variables were access to
general medical care and the initiation of treatment for HIV and
hepatitis. However, in the current study, we have reviewed and
reported the results on the outcome of the initiation of HIV
treatment only.
2.1. Data sources for existing reviews
Two reviewers (LBM and BFS) independently searched for the
presence of systematic reviews or protocols similar to the one used
for this review. This search was conducted in the CochraneDatabase of Systematic Reviews, the Database of Abstracts of
Reviews of Effects, the Campbell Library of Systematic Reviews,
and the National Institute for Health and Care Excellence. No
similar review was found.
2.2. Evidence search strategy
We used sets of prepared Boolean phrases and search terms to
retrieve evidence from various medical and academic databases.
Similarly, the two reviewers (LBM and BFS) independently
conducted a literature search in PubMed, the Education Resources
Information Center, PsycINFO, the European Monitoring Centre for
Drugs and Drug Addiction, the National Institute on Drug Abuse,
the United Nations Ofﬁce on Drugs and Crime, and World Health
Organization databases. For the PubMed database, we used a
Boolean combination search term (Supplementary ﬁle 2). We used
similar text words to conduct searches in the other databases. We
also conducted a hand search from references of journal articles
that we retrieved. The last search for this review was conducted on
1st November 2014. The searches for various databases were
conducted within three months. We limited our screening to
studies which were reported in English language. No limit was set
for the dates of publication of the articles. The two reviewers
compared their results for each database, resolved minor
differences and reached a ﬁnal article inclusion list. We adopted
the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) checklist (Supplementary ﬁle 3) and used the
PRISMA ﬂow diagram to retrieve and report the evidence
(Figure 1).28
2.3. Inclusion and exclusion criteria
We included studies of prospective cohort design with control
groups or those comparing an outcome before and after the
intervention. We also included cross-sectional studies with control
groups. We also searched for randomized controlled trials however
none was found which addressed our PICO question. We excluded
qualitative studies, reviews, case reports, or editorials.
2.4. Data extraction
The two researchers (LBM and BFS) independently extracted
data. The differences were resolved by consensus. We conducted
data extraction using an excel spreadsheet. It contained the
following elements: study author, year of publication, country in
which the study was conducted, study design, intervention
characteristics including the medications used for opioid ago-
nist/antagonist therapy and length of follow-up of the interven-
tion, participants of the study, and results of the study.
2.5. Data synthesis and analysis
Five studies were included in this review.29–33 A narrative
synthesis was described for all ﬁve studies and a meta-analysis was
conducted for four studies29,30,32,33 for the outcome of ART
initiation (Figure 1). A ﬁfth study31 was not included in the
meta-analysis because it had no control group.
For meta-analysis, we calculated the odds ratio (OR) and 95%
Conﬁdence Interval (CI) using the Mantel-Haenszel analysis in a
random-effect model. We assessed heterogeneity of studies using
Chi-square (x2) and I2 statistics. The I2 statistic describes the
percentage of variation in the observed estimates of effect from the
included studies due to heterogeneity rather than chance. We used
an alpha level of 0.05 for meta-analysis, except for testing
heterogeneity, where we used p < 0.10. We used Review Manager
5.334 to conduct meta-analysis.
Figure 1. PRISMA Flow diagram to show the systematic review process (PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses).
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3.1. Systematic review process
Figure 1 shows the results of the review process. We identiﬁed
2,901 articles from our database searches. Of them, we identiﬁed
1,041 articles from PubMed and 1,860 articles from other databases
and hand search. After excluding duplicates, we screened 2,891
articles based on titles and abstracts, and retrieved 72 articles for full
text review. We excluded 67 articles for various reasons including
different outcome (n = 47), lack of a control groups (n = 7), policy
papers (n = 6), different interventions (n = 3), lack of an interven-
tions (n = 2), overlapping participants (n = 1) and a case report
(n = 1). Five studies were included in this review.29–33
3.2. Description of included studies
Of ﬁve included studies, two were conducted in the USA31,32
and others in Switzerland,29 Canada30 and Ukraine.33 Regarding
the study design, three were prospective cohort studies29–31 and
two were cross-sectional studies.32,33 For opioid agonist therapy,
people who inject drugs received methadone, buprenorphine,
naloxone, or legal heroin (Table 1).
3.3. Study quality assessment
The two researchers (LBM and BFS) independently conducted
study quality assessment. We assessed risk of bias, using a Risk of
Bias Assessment for Non-randomized Studies tool for observation-
al studies.35 We assessed six types of risk of biases: selection of
participants, confounding variables, measurement of exposure,
blinding of outcome assessments, incomplete outcome data, andselective outcome reporting. All ﬁve included studies had an
unclear risk of bias for blinding of outcome assessments and three
studies had an unclear risk of bias for incomplete outcome data
assessment30,31,33 (Table 2).
We conducted grading of evidence for four studies29,30,32,33
included in the meta-analysis. We evaluated these studies using
the Grades of Recommendation, Assessment, Development and
Evaluation (GRADE) technique.36 The quality of studies was very
low, and inconsistency was substantial however the risk of bias,
indirectness and imprecision were not serious (Table 3). The
quality of the studies was very low because of the observational
type of the study designs of included studies, which are rated low
quality and substantial heterogeneity observed in the meta-
analysis of the included studies. We used the online Guideline
Development Tool37 to prepare the GRADE table.
3.4. Association of opioid agonist therapy with ART initiation
Table 4 shows a narrative synthesis of all ﬁve studies included
in this review. A prospective cohort study conducted in Canada,
reported a higher rate of ART initiation among participants on
opioid agonist therapy (methadone) compared to those who were
not on such therapy (64.2% vs. 44.8%; log-rank p = 0.004).30
Another prospective cohort study without a control group
conducted in the USA showed that, compared to baseline,
participants who were on suboxone (buprenorphine/naloxone)
were more likely to receive ART as the study observation time
increased (p < 0.05).31 Furthermore, the proportion of HIV-
positive people who inject drugs who initiated ART was higher
among participants on opioid agonist therapy (methadone)
compared to that among participants not on such therapy in a
cross-sectional study in the USA (88.1% vs. 33.8%; p = 0.001).32
Table 2
Assessment of risk of bias for non-randomized observational studies
Author Selection
of participants
Confounding
variables
Measurement
of exposure
Blinding
of outcome
assessments
Incomplete
outcome data
Selective
outcome reporting
Weber 200929
Uhlmann 201030
Altice 201131
Sambamoorthi 200032
Bachireddy 201433
Indicates low risk of bias Indicates unclear risk of bias.
Table 1
Description of included studies
Author Country Study design Intervention drug Intervention/study characteristics Length of the OT study
Weber 200929 Switzerland Prospective
cohort
Methadone/
buprenorphine/
legal heroin
The Swiss HIV Cohort Study (SHCS)
consists of HIV positive individuals
treated at HIV outpatient clinics and
district hospitals. Opioid agonist
therapy (OT) is not carried out by the
SHCS centers but by specialized
institutions or private physicians.
ART initiation data were obtained
through self-report.
10 years
Uhlmann
201030
Canada Prospective cohort Methadone The prospective cohort consists of HIV-
positive PWID who complete a
questionnaire at baseline and semi-
annually.
ART initiation data were obtained
through self-report which was
supported by a centralized province-
wide ART dispensation program and a
conﬁdential record linkage.
8 years
Altice 201131 USA Prospective cohort Buprenorphine/
Naloxone
Participants were from HIV clinical
sites that provide integrated HIV
primary care and buprenorphine/
naloxone treatment for opioid
dependence.
ART initiation data were obtained
through self-report and conﬁrmed by
chart review.
12 months
Sambamoorthi
200032
USA Cross-sectional Methadone Participants were PWID who had AIDS.
Data were retrieved from databases
namely AIDS Registry, Medicaid paid
claims and AIDS Community Care
Alternatives Program.
ART initiation data were obtained from
pharmacy data.
8 years
Bachireddy
201433
Ukraine Cross-sectional Buprenorphine/
methadone
The intervention group consisted of
participants from Integrated/co-
located clinic (ICL) or non-co-located
clinic (NCL) while the control group
consisted of participants from harm
reduction and outreach (HRO) sites. ICL
clinics provide treatment and screening
for tuberculosis, HIV and opioid
dependence using OT. NCL provide
opioid dependence treatment using OT
with substance abuse treatment
counseling. HRO sites provide case
management, referral for services such
as HIV and tuberculosis, syringe
exchange and psychosocial counseling.
ART initiation data were obtained
through self-report.
Participants in the intervention
group had been enrolled >
3 months. Those in the control
group (HRO) did not require to
register
HIV, human immunodeﬁciency virus; PWID, people who inject drugs; AIDS, acquired immunodeﬁciency syndrome; OT, opioid agonist therapy
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Table 3
GRADE proﬁle of 4 studies included in the meta-analysis
Quality assessment Summary of ﬁndings
No of patients Effect Quality
No of
studies
Study design Risk of
bias
Inconsistency Indirectness Imprecision Other
considerations
No OT OT Relative
(95% CI)
Absolute
(95% CI)
4a Observational
studies
Not serious Serious Not
serious
Not
serious
None 748/1245
(60.1%)
388/1047
(37.1%)
OR 1.68
(1.03 to 2.73)
116 more
per 1000 (from
7 more to
203 more)
***
Very low
GRADE, Grades of Recommendation, Assessment, Development and Evaluation; OT, opioid agonist therapy.
a Studies:29,30,32,33
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between participants on opioid agonist therapy (methadone/
buprenorphine/legal heroin) and those not on such therapy in a
prospective cohort study in Switzerland was not statistically
signiﬁcant (20.1% vs. 20.6; p = 0.9).29 Also, the difference in
proportion of ART initiation between participants on opioid
agonist therapy (buprenorphine/methadone) and those not on
such therapy in a cross-sectional study in Ukraine was not
statistically signiﬁcant (33.8% vs. 26.3%; p = 0.19).33
Meta-analysis of the four studies showed that opioid agonist
therapy is positively associated with ART initiation among people
who inject drugs (pooled OR: 1.68; 95% CI: 1.03-2.73). However,
heterogeneity may be substantial (x2 = 10.61; I2 = 72%; p = 0.01)
(Figure 2).
4. Discussion
In this systematic review, opioid agonist therapy is positively
associated with ART initiation among HIV-positive people who
inject drugs. Individuals with opioid dependence are more likely toTable 4
Association of opioid agonist therapy on ART initiation - a narrative synthesis
Author Country Study design Total sample 
Weber 200929 Switzerland Prospective cohort
study with a
control group
748 participant
OT, 141 not on 
Uhlmann 201030 Canada Prospective cohort
study with a
control group
231 participants
176 not on OT)
Altice 201131 USA Prospective cohort:
pre-post
intervention study
295 at baseline,
follow-up (All p
on OT, no contr
Sambamoorthi 200032 USA Cross-sectional
study with a
control group
1017 participan
OT, 833 not on 
Bachireddy 201433 Ukraine Cross-sectional
study with a
control group
296 participant
OT, 95 not on O
OT, opioid agonist therapy; ART, antiretroviral therapy; IQR, interquartile range.be mentally, physically, and socially disadvantaged especially
when they have been on opioids for a long time.38,39 Treatment
with opioid agonist therapy has been shown to improve physical
and social functioning for these individuals.23,24 People who inject
drugs on opioid agonist therapy are more likely to achieve physical
and social stabilization, and as a result, they are more likely to
overcome the barriers associated with access to medical care and
improve their ART initiation.
Of ﬁve studies, three reported that, HIV-positive people
receiving opioid agonist therapy initiated ART more than those
not receiving opioid agonist therapy. Barriers of access to health
care might have contributed to the lack of beneﬁt of opioid agonist
therapy on ART initiation in the two studies conducted in
Switzerland29 and Ukraine.33 In Switzerland, ART could be easily
accessed therefore the individual factors might have played a
major factor. More individuals were actively injecting drugs in the
intervention group than in the control group in the study
conducted in Switzerland.29 Active injecting drug use might have
inﬂuenced them to prioritize drug use than focusing on their
personal health.40HIV disease severity Results
s (607 on
OT)
At baseline, median (IQR)
nadir CD4 cell count was
245 (120–470) in the OT
group and 277 (156–512)
cells/mL in the non-OT
group; 17.3% and 9.2% had
AIDS in the OT and non-OT
groups respectively
Between baseline and last visit,
there was no a statistically
signiﬁcant difference in
initiating ART between
participants on OT and those
not on OT (20.1% vs. 20.6;
p = 0.9).
 (55 on OT, At baseline, viral load (
100,000 copies/mL) in the
OT and non-OT: 24% vs.
33%, p = 0.237; CD4 count
(< 200 cells/mm3): 16% vs.
22%, p = 0.312.
24 months after recruitment,
the rate of ART initiation was
higher among participants on
OT than those not on OT (64.2%
vs. 44.8%; log-rank p = 0.004).
 187 at
articipants
ol group)
At baseline, mean CD4
count, 354.9 cells/mL
(261 participants).
At baseline, 59.7% of
participants were on ART and at
follow-up 68.4% of participants
were on ART. Compared with
baseline, participants were
more likely to receive ART as
the observation time increased
(p < 0.05).
ts (184 on
OT)
All participants had AIDS. The proportion of ART initiation
was higher among participants
on OT than those not on OT
(88.1% vs. 73.8%; p < 0.001).
s (201 on
T)
CD4 monitoring in the past
6 months: 87.6% in the OT
and 64.8% in the non-OT
group.
The proportion of ART initiation
was not statistically signiﬁcant
among participants on OT
compared to those not on OT
(33.8% vs. 26.3%; p = 0.19).
Figure 2. Effectiveness of OST on the initiation of ART among people who inject drugs–meta-analysis (OST, opioid substitution therapy; ART, antiretroviral therapy).
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following studies, although they did not meet the inclusion criteria
for this review. One of them is a cross-sectional study in Ireland
where receiving ART was positively associated with being on
methadone maintenance treatment among people who inject
drugs.15 In another study in Ukraine, a total of 207 people who use
drugs were enrolled in the national buprenorphine maintenance
treatment program nine months after it had started. Of them, 55%
were HIV-positive and 25% had started ART.41 Moreover, in a
cohort study in Indonesia among 223 people who inject drugs
enrolled in the study, the methadone clinic was responsible for
diagnosing 31.9% of HIV-positive participants and initiating ART
for 45.7% of the participants.16 Lastly, ART use was positively
associated with use of methadone maintenance treatment among
people who inject drugs in cohort studies in Canada.24,42
This study has several limitations. First, the included studies
were observational (cohort studies, cross-sectional studies and a
pre-post interventional study with no control group). In these
studies unmeasured motivational and related factors might have
led people who inject drugs engaging in opioid agonist therapy to
also be more diligent in seeking ART. To control for the differences
of the included studies, a risk of bias assessment was conducted for
all ﬁve included studies, and graded the quality of evidence for four
of studies included in the meta-analysis. Second, in meta-analysis,
heterogeneity might be substantial. Substantial heterogeneity
might be due to the differences in duration of follow-up of the
interventions of the included studies that ranged from three
months to thirteen years. Third, most of the studies were from
developed countries and only one study was from a developing
country. Therefore, it may not be possible to generalize these
results to all countries with the problem of injection drug use.
Despite these limitations, this is the ﬁrst systematic review that
examined the association of opioid agonist therapy with ART
initiation among HIV-positive people who inject drugs.
5. Conclusions
Five studies were included in this systematic review. Three of
them reported that HIV-positive people receiving opioid agonist
therapy, initiated ART more than those not receiving opioid agonist
therapy. The overall effect size through meta-analysis shows that
opioid agonist therapy is positively associated with ART initiation
among HIV-positive people who inject drugs. However, these
results should be interpreted with caution due to substantial
heterogeneity observed among the included studies.
For people who inject drugs, their improved access to opioid
agonist therapy and ART is crucial. To improve ART initiation
among them, opioid agonist therapy should be scaled up. When
they are on opioid agonist therapy, they can receive ART at the
opioid agonist therapy site. Also, they can be referred to off-site
HIV care and treatment centers and then still initiate ART.43
However, people who inject drugs face many barriers in accessing
health care including lack of transport. Therefore, these barriers
should be considered while establishing opioid agonist therapy
programs which provide medications for opioid dependence onlywithout HIV care and treatment at the same site. Furthermore, it is
important to conduct more assessments to examine the associa-
tion between opioid agonist therapy and ART initiation using
cohort study designs or cross-sectional studies with control groups
as only ﬁve studies were included in this systematic review.
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